Table 4 Follow-up information at 6 months
Total N (%) | Tele-monitoring N (%) | Hospital Monitoring N (%) | P-value | |
|---|---|---|---|---|
Number of transmissions from consultation room | ||||
0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.26 |
1 | 41 (83.7) | 21 (84.0) | 20 (83.3) | |
2 | 6 (12.2) | 2 (8.0) | 4 (16.7) | |
3 | 2 (4.1) | 2 (8.0) | 0 (0.0) | |
Transmissions from patients home | ||||
0 | 29 (59.2) | 5 (20.0) | 24 (100) | < 0.001 |
3–5 | 15 (30.6) | 15 (60.0) | 0 (0.0) | |
6–8 | 5 (10.2) | 5 (20.0) | 0 (0.0) | |
Extra transmissions from patients home | ||||
0 | 45 (91.8) | 21 (84.0) | 24 (100) | 0.12 |
1 | 1 (2.0) | 1 (4.0) | 0 (0.0) | |
3 | 3 (6.2) | 3 (12.0) | 0 (0.0) | |
Cardiovascular adverse events | ||||
None | 46 (93.9) | 23 (92.0) | 23 (95.8) | 0.40 |
PCI | 1 (2.0) | 1 (4.0) | 0 (0.0) | |
Angina | 1 (2.0) | 0 (0.0) | 1 (4.2) | |
Lead dislodgement ×2 | 1 (2.0) | 1 (2.0) | 0 (0.0) | |
Changes of medication | ||||
0 | 33 (67.3) | 17 (68.0) | 16 (66.7) | 0.11 |
1 | 7 (14.3) | 5 (20.0) | 2 (8.3) | |
2 | 3 (6.1) | 1 (4.0) | 2 (8.3) | |
3 | 4 (8.2) | 0 (0.0) | 4 (16.7) | |
4 | 2 (4.1) | 2 (8.0) | 0 (0.0) | |
Changes of pacemakers reprogramming | ||||
0 | 34 (69.4) | 16 (64.0) | 18 (75.0) | 0.34 |
1 | 13 (26.5) | 7 (28.0) | 6 (25.0) | |
2 | 2 (4.1) | 2 (8.0) | 0 (0.0) | |
Hospitalizations days after implant | ||||
0 | 30 (61.2) | 14 (56.0) | 16 (66.7) | 0.55 |
1 | 14 (28.6) | 7 (28.0) | 7 (29.2) | |
2 | 4 (8.2) | 3 (12.0) | 1 (4.2) | |
5 | 1 (2.0) | 1 (2.0) | 0 (0.0) | |
Days hospitalizated | ||||
0 | 30 (61.2) | 14 (56.0) | 16 (66.7) | 0.54 |
1–5 | 12 (24.5) | 6 (24.0) | 6 (25.1) | |
6–10 | 4 (8.1) | 2 (8.0) | 2 (8.4) | |
+ 10 | 3 (6.0) | 3 (12.0) | 0 (0.0) | |
Reasons for hospitalization | ||||
None | 30 (61.2) | 14 (56.0) | 16 (66.7) | 0.37 |
Others | 6 (12.3) | 3 (12.0) | 3 (12.5) | |
Cancer | 1 (2.0) | 1 (4.0) | 0 (0.0) | |
Coronary problems | 9 (18.4) | 4 (16.0) | 5 (20.8) | |
PM disfuction | 3 (6.1) | 3 (12.0) | 0 (0.0) | |